Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.96 |
| ▸ | TARDBP | Q13148 | 2/20 | 0.96 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.96 |
| ▸ | MEN1 | O00255 | 1/20 | 0.96 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.96 |
| ▸ | LMNA | P02545 | 1/20 | 0.96 |
| ▸ | POLB | P06746 | 1/20 | 0.96 |
| ▸ | THRB | P10828 | 1/20 | 0.96 |
| ▸ | TSHR | P16473 | 1/20 | 0.96 |
| ▸ | ACHE | P22303 | 1/20 | 0.96 |
| ▸ | APEX1 | P27695 | 1/20 | 0.96 |
| ▸ | RECQL | P46063 | 1/20 | 0.96 |
| ▸ | BLM | P54132 | 1/20 | 0.96 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.96 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.96 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.96 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.96 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thioctic Acid SCHEMBL4898896 | 1.00 | HSD17B10 (0.96) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| Lipoic Acid, Alpha SCHEMBL1981737 | 0.98 | HSD17B10 (1.00) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| Lipoic Acid, Alpha SCHEMBL2128472 | 0.98 | HSD17B10 (1.00) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| Lipoic Acid, Alpha SCHEMBL51065 | 0.98 | HSD17B10 (1.00) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| Thioctic Acid SCHEMBL4611014 | 0.98 | HSD17B10 (1.00) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| Thioctic Acid SCHEMBL7924 | 0.98 | HSD17B10 (1.00) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL25257437 | 0.96 | HSD17B10 (0.96) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| Thioctic Acid SCHEMBL6037631 | 0.96 | HSD17B10 (0.96) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| Lipoic Acid, Alpha SCHEMBL6037633 | 0.96 | HSD17B10 (0.96) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL7914749 | 0.96 | HSD17B10 (0.96) | HSD17B10KMT2ATARDBPCYP2C9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117924347-A | Preparation method of monosulfur organosilane coupling agent | 江西宏柏新材料股份有限公司 | 2024-04-26 | — | — | CN | claimed |
| CN-117186142-A | Process for preparing 3-octanoyl thiopropyl triethoxysilane | 浙江开化合成材料有限公司 | 2023-12-08 | — | — | CN | claimed |
| US-20080234380-A1 | Compositions and method for treatment of chronic inflammatory diseases | SHAPIRO HOWARD K | 2008-09-25 | — | — | US | claimed |
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | SECANT PHARMA, LLC | 2005-04-28 | — | — | US | claimed |
| CN-117924347-A | Preparation method of monosulfur organosilane coupling agent | 江西宏柏新材料股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-117924347-A | Preparation method of monosulfur organosilane coupling agent | 江西宏柏新材料股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-117186142-A | Process for preparing 3-octanoyl thiopropyl triethoxysilane | 浙江开化合成材料有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-117186142-A | Process for preparing 3-octanoyl thiopropyl triethoxysilane | 浙江开化合成材料有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-114682183-A | Continuous flow production method of lipoic acid bulk drug | 江苏同禾药业有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-104387364-B | L-ornithine lipoic acid composite salt and preparation method and application thereof | 南京工业大学 | 2016-11-16 | — | — | CN | disclosed |
| CN-105001195-A | New crystal form of R(+)-thioctic acid-L-lysinate and preparation method thereof | NANJING HAIRONG PHARMACEUTICAL TECHNOLOGY CO LTD | 2015-10-28 | — | — | CN | disclosed |
| CN-104387364-A | L-ornithine lipoic acid composite salt and preparation method and application thereof | NANJING UNIVERSITY OF TECHNOLOGY | 2015-03-04 | — | — | CN | disclosed |
| CN-101607955-B | Preparation method for low-residue lipoic acid | SHANGHAI JINLI CHEMICAL CO LTD | 2012-11-28 | — | — | CN | disclosed |
| CN-101607955-A | A kind of preparation method of low-residue lipoic acid | SHANGHAI JINLI CHEMICAL CO LTD (CN) | 2009-12-23 | — | — | CN | disclosed |
| US-6348490-B1 | RELEASING AND FORMING RACEMIC MIXTURES | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 2002-02-19 | — | — | US | disclosed |
| US-5990152-A | ACID RESISTANT TO GASTRIC JUICE; RAPIDLY DISSOLVES IN THE DUODENUM; GROUP 1A AND 2A METAL SALTS; AMMONIUM AND AMINE SALTS; STORAGE STABILITY | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 1999-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | PCCA, HMGB1, PTGES | HSD17B10 1039/4885KMT2A 1830/4885TARDBP 2554/4885 |
| US-20080234380-A1 | Compositions and method for treatment of chronic inflammatory diseases | HMGB1, PCCA, QSOX1 | HSD17B10 1124/4885KMT2A 1426/4885TARDBP 2637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.